Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy in systemic lupus erythematosus vs. placebo, according to data published in ...
It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...
In patients with active systemic lupus erythematosus unresponsive to conventional hydroxychloroquine-based therapy, adding mepacrine shows improved outcomes with few and mild side effects.
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...
New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...
The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...
Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...
The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback